Next, we compared the efficacy of the hexatherapy regimen versus hexatherapy regimen minus one treatment modality (ie, the hexatherapy combination without OX40+4-1BB, Ad-CEA+N-803, PD-L1, or docetaxel) to assess the contribution of each treatment modality to the anti-tumor effect of the hexatherapy combination (figure 2D, E). This evidence concerns the gene CEACAM5 and neoplasm.